⌘K

16:00:03·72d

SECFilingvia Quantisnow

Amendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.

ByQuantisnow·Wall Street's wire, on your screen.

IKT· Inhibikase Therapeutics Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

IKT
Inhibikase Therapeutics Inc.
Health Care

Recent analyst ratings

Mar 4UpdateLadenburg Thalmann$4.00
Jan 21UpdateBofA Securities$6.00
Dec 26UpdateH.C. Wainwright$8.00
Dec 11UpdateCantor Fitzgerald$4.00
Feb 12UpdateH.C. Wainwright-
Jul 15UpdateJonesTrading$12.00

Related

SEC22h
SEC Form DEFA14A filed by Inhibikase Therapeutics Inc.
SEC22h
SEC Form DEF 14A filed by Inhibikase Therapeutics Inc.
SEC10d
SEC Form PRE 14A filed by Inhibikase Therapeutics Inc.
SEC24d
Inhibikase Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
PR24d
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
PR28d
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SEC35d
SEC Form S-8 filed by Inhibikase Therapeutics Inc.
SEC35d
SEC Form 10-K filed by Inhibikase Therapeutics Inc.